EQRx, Inc. (EQRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
EQRX Stock Price Chart Interactive Chart >
EQRX Price/Volume Stats
| Current price | $4.58 | 52-week high | $10.49 |
| Prev. close | $4.51 | 52-week low | $2.63 |
| Day low | $4.34 | Volume | 2,075,410 |
| Day high | $4.63 | Avg. volume | 1,733,152 |
| 50-day MA | $4.55 | Dividend yield | N/A |
| 200-day MA | $6.39 | Market Cap | 2.23B |
EQRx, Inc. (EQRX) Company Bio
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase I clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Latest EQRX News From Around the Web
Below are the latest news stories about EQRx Inc that investors may wish to consider to help them evaluate EQRX as an investment opportunity.
Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung CancerPivotal Phase 3 GEMSTONE-302 trial met key secondary endpoint of prolongation of overall survival with sugemalimab plus chemotherapy versus placebo plus chemotherapyOverall survival benefit demonstrated regardless of tumor pathologic subtype or PD-L1 expression levels CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, along with it |
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung CancerResults from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent chemoradiotherapy Concurrently published results from the pivotal Phase 3 GEMSTONE-302 study demonstrated PFS benefit with sugemalimab plus chemotherapy in first-line systemic treatment of patients with Stage IV NSCLC, regardless of tumor pathologic subtype o |
EQRx Enters Memorandum of Understanding with CVS Health to Create Cost Savings and Improve Patient Access to Innovative MedicinesThe two companies will explore opportunities for a long-term, strategic partnership spanning the CVS Health enterpriseIncludes CVS Caremark, the leading pharmacy benefit manager in the U.S., covering 1 in 3 Americans – nearly 110 million livesInitial focus will be on EQRx’s two lead oncology programs with future therapies expected to follow CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering im |
EQRx and Geisinger Sign Memorandum of Understanding to Provide Access to Innovative Cancer Medicines at Radically Lower CostsProvides roadmap to commercial agreement between EQRx and Geisinger, a U.S.-based integrated delivery networkPotential to provide access to affordable treatments in areas of high-cost burden for more than 1 million people within Geisinger health systems CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced it has signe |
EQRx to Present at the 40th Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that Melanie Nallicheri, chief executive officer, will present virtually during the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10 at 3:45 p.m. ET. A live and archived webcast of the presentation will be available by visiting the Investors secti |
EQRX Price Returns
| 1-mo | N/A |
| 3-mo | 10.90% |
| 6-mo | -32.84% |
| 1-year | -55.58% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -32.84% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...